{
    "organizations": [],
    "uuid": "f884cff50de94ed320c853c60c119a8b3021a085",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-the-medicines-q4-gaap-loss-per-sha/brief-the-medicines-q4-gaap-loss-per-share-2-19-from-continuing-operations-idUSASB0C6M7",
    "ord_in_thread": 0,
    "title": "BRIEF-The Medicines Q4 GAAP Loss Per Share $2.19 From Continuing Operations",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Feb 21 (Reuters) - Medicines Co:\n* THE MEDICINES COMPANY REPORTS FOURTH-QUARTER AND FULL-YEAR 2017 BUSINESS AND FINANCIAL RESULTS\n* Q4 GAAP LOSS PER SHARE $2.19 FROM CONTINUING OPERATIONS * Q4 REVENUE $8.6 MILLION * Q4 ADJUSTED NON-GAAP LOSS PER SHARE $0.61 FROM CONTINUING OPERATIONS\n* WORLDWIDE NET REVENUE WAS $8.6 MILLION IN Q4 OF 2017 VERSUS $17.4 MILLION IN Q4 OF 2016 Source text for Eikon: Further company coverage:\n ",
    "published": "2018-02-21T20:10:00.000+02:00",
    "crawled": "2018-02-22T18:01:58.000+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "feb",
        "reuters",
        "medicine",
        "co",
        "medicine",
        "company",
        "report",
        "business",
        "financial",
        "result",
        "q4",
        "gaap",
        "loss",
        "per",
        "share",
        "continuing",
        "operation",
        "q4",
        "revenue",
        "million",
        "q4",
        "adjusted",
        "loss",
        "per",
        "share",
        "continuing",
        "operation",
        "worldwide",
        "net",
        "revenue",
        "million",
        "q4",
        "versus",
        "million",
        "q4",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}